Overview

FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary

Status:
Not yet recruiting
Trial end date:
2024-02-22
Target enrollment:
Participant gender:
Summary
This is a prospective single arm cohort study designed to evaluate the diagnostic ability of 68Ga-FAPI-PET/CT scan in determining likely tissue of origin in Cancer of Unknown Primary (CUP) patients not identified by standard of care. Patients with CUP will be either treatment naïve or starting second-line treatment.
Phase:
N/A
Details
Lead Sponsor:
Peter MacCallum Cancer Centre, Australia
Treatments:
FAPI-46